The journalist’s organs had been severely damaged by the disease, which causes a buildup of amyloid proteins in the body.

After a long career as an accomplished TV and radio journalist for programs like AM, This Day Tonight and Beyond 2000, Iain ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of hereditary amyloidosis.

In its 10-Q report, Alnylam Pharmaceuticals stated that as of March 31, 2025, it had an accumulated deficit of $7.35 billion ...

UK MHRA grants marketing approval for BridgeBio Pharma’s Beyonttra to treat ATTR-CM: Palo Alto, California Wednesday, April 30, 2025, 16:00 Hrs [IST] BridgeBio Pharma, Inc., a n ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Halozyme Therapeutics (NASDAQ:HALO) announced Monday that an expert panel of the EU ...

The following is a summary of “Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages,” published in the April 2025 issue of Journal of Neurology by ...

LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...